Concentration of hormone tied to CHD risk
Higher concentrations of the fibroblast growth factor 23 hormone were associated with elevated risk for CHD, according to new data from the REGARDS study.
The researchers measured fibroblast growth factor 23 (FGF23) concentrations in 829 participants from the REGARDS study who developed CHD and 812 randomly selected participants from REGARDS who did not have CHD. The cohort random sample was then weighted back to the overall cohort (n = 22,127; mean age, 64 years; 59% women; 43% black).
Participants were stratified into quartiles based on FGF23 concentration, and the association of FGF23 concentration with incident CHD was analyzed. The researchers also assessed whether race, sex or chronic kidney disease modified the relationship between FGF23 concentration and incident CHD.
At baseline, older age, lower estimated glomerular filtration rate, higher urine albumin-to-creatinine ratio and female sex were associated with elevated FGF23 concentration, Bhupesh Panwar, MD, from the department of medicine, University of Alabama at Birmingham, and colleagues wrote.
After adjustment for CHD risk factors and kidney function, higher FGF23 concentrations were associated with elevated incident CHD risk (HR for fourth vs. first quartile = 2.15; 95% CI, 1.35-3.42).
The association was more pronounced in men than in women (P for interaction = .06), but the differences by sex disappeared after adjustment for hormone therapy in women (HR for fourth vs. first quartile in men = 2.4; 95% CI, 1.3-4.42; HR for fourth vs. first quartile in women = 2.34; 95% CI, 1.04-5.27), according to the researchers. The results were similar when each sex was divided into quartiles.
“The results of this study support an association of FGF23 concentration with incident CHD among community-living adults and suggest that sex hormone use and differences in the distribution of FGF23 by sex may be important to consider when assessing the relationship between FGF23 concentration and CHD in older adults,” Panwar and colleagues wrote. – by Erik Swain
Disclosures: Panwar reports he received a grant from Keryx Biopharmaceuticals. Please see the study for all other authors’ relevant financial disclosures.